Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05888532 · ClinicalTrials.gov registry record · Phase 1
64Cu-GRIP B in Patients With Advanced Malignancies
A Phase 1 study of Prostate Cancer and Advanced Solid Tumor, sponsored by Rahul Aggarwal.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
- 1
- Study location
NCT05888532 is a Phase 1 study of Prostate Cancer and Advanced Solid Tumor that is actively recruiting participants, run by Rahul Aggarwal. The registered enrollment target is 91 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05888532, a Phase 1 study of Prostate Cancer and Advanced Solid Tumor, is actively recruiting participants, sponsored by Rahul Aggarwal.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I/II clinical trial evaluates if using a radiotracer targeting granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64 Cu-GRIP B) with positron emission tomography (PET) imaging can be safe and useful for detecting granzyme B (GrB) in patients with advanced cancers that has spread to nearby tissue or lymph nodes (advanced). Granzyme B (GrB) is a biomarker produced by immune cells in response to immunotherapy, which may highlight tumors that are more likely to respond to treatment. The study population is focused on genitourinary (GU) malignancies, including renal cell and urothelial cancer, two tumor types with high mutational burden and tumor infiltrating lymphocytes compared to other tumor types, and have a predictable response rate at the population level to immune checkpoint inhibitors. The information gained from this trial may allow researchers to develop future trials where 64Cu-GRIP B PET may serve as a biomarker to monitor early response to immunomodulatory therapies which are used to stimulate or suppress the immune system and may help the body fight cancer.
Conditions Studied
Interventions
- PROCEDURE Positron Emission Tomography (PET)
- DRUG Copper-64 labeled Granzyme B (64Cu-GRIP B)
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2023-05-25 |
| Est. Completion | 2027-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05888532
The ClinicalTrials.gov registry entry for NCT05888532 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (85% lower). The listed sponsor is Rahul Aggarwal, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Positron Emission Tomography (PET) is the first listed.
NCT05888532 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05888532 about?
NCT05888532 is a clinical study titled "64Cu-GRIP B in Patients With Advanced Malignancies". This phase I/II clinical trial evaluates if using a radiotracer targeting granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64 Cu-GRIP B) with positron emission tomography (PET) imaging can be safe and useful for detecting granzyme B (GrB) in patien...
What is the current status of trial NCT05888532?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2023-05-25. Estimated completion is 2027-01-31.
What conditions does trial NCT05888532 study?
This clinical trial studies the following conditions: Prostate Cancer, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Castration-Resistant Prostate Cancer, Renal Cancer.
What interventions are being tested in trial NCT05888532?
The interventions under investigation include: Positron Emission Tomography (PET) (PROCEDURE), Copper-64 labeled Granzyme B (64Cu-GRIP B) (DRUG).
Who is sponsoring clinical trial NCT05888532?
This trial is sponsored by Rahul Aggarwal, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05888532 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.